Prostate Cancer Ontology
Center for Systems Biology, Sichuan University West China Hospital, Sichuan China
跳过导航链接。
折叠 前列腺癌前列腺癌
展开 前列腺癌流行病学前列腺癌流行病学
展开 前列腺癌的诊断前列腺癌的诊断
折叠 前列腺癌的治疗前列腺癌的治疗
展开 延期治疗延期治疗
展开 外科手术外科手术
展开 放射疗法放射疗法
展开 冷冻疗法冷冻疗法
展开 激素疗法激素疗法
展开 化疗化疗
展开 去势抵抗性前列腺癌(CRPC)去势抵抗性前列腺癌(CRPC)
展开 转移性前列腺癌转移性前列腺癌
折叠 其他治疗方式其他治疗方式
展开 老年男性前列腺癌的治疗老年男性前列腺癌的治疗
展开 局部前列腺癌除手术和放疗以外的其他初级治疗选择局部前列腺癌除手术和放疗以外的其他初级治疗选择
展开 局部前列腺癌患者的治疗后生活质量局部前列腺癌患者的治疗后生活质量
折叠 根治性目的治疗后仅限PSA复发的治疗根治性目的治疗后仅限PSA复发的治疗
生化失败的自然史
Preferred Name Natural history of biochemical failure
Definition Once a PSA relapse has been diagnosed, it is important to determine whether the recurrence has developed at local or distant sites. The risk of subsequent metastases and PCSM may be predicted by the initial clinical factors (e.g. T-category, PSA, biopsy Gleason score). If the patient has undergone RP, the pathological outcomes of the surgery (e.g. pathologic T-category and prostatectomy Gleason score, nodal and margin status) may provide further information. Beyond pre- and posttreatment clinico-pathological factors, PSA kinetics (PSA doubling-time (PSA-DT) and interval to PSA failure) may be used to estimate the risk of metastases and subsequent PCSM.
Synonyms & Abbreviations Natural history of biochemical failure
ReferenceCode NA
ReferenceURL NA
PMID NA
Copyright (C) 2022 Institutes for Systems Genetics, Sichuan University West China Hospital. All Rights Reserved.